Stock listing
NASDAQ:LYCA Lycia Therapeutics, Inc. Stock
Home listing (NASDAQ) of Lycia Therapeutics, Inc.
Follow Lycia Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:LYCA
$33.07 USD +1.72 (+5.5%)
Close on Nov 20, 2026
- Day range
- $31.01 – $34.59 USDNov 20, 2026
- Volume
- 422,136 sharesNov 20, 2026
- Market cap
- $1.72B USDAt the close on Nov 20, 2026 · price × 52.09M shares outstanding
- Traded on an average day
- $13.05M USDMedian day 316,082 shares · last 3 months, Oct 23, 2026 – Nov 20, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LYCA · Home | $33.07 USD | +1.72 (+5.5%) | 422,136 | $31.86 | $34.59 | $31.01 | $31.35 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Oct 23, 2026 – Nov 20, 2026 · NASDAQ:LYCA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $33.07 | +1.72 | +5.5% | $31.86 | $34.59 | $31.01 | 422,136 | |
| $31.35 | +0.43 | +1.4% | $30.45 | $32.85 | $30.45 | 383,616 | |
| $30.92 | +2.31 | +8.1% | $28.62 | $31.72 | $28.62 | 496,158 | |
| $28.61 | -2.59 | -8.3% | $31.23 | $32.40 | $28.18 | 250,870 | |
| $31.20 | -1.63 | -5.0% | $32.83 | $33.00 | $31.20 | 189,539 | |
| $32.83 | +1.39 | +4.4% | $32.00 | $33.44 | $30.90 | 496,078 | |
| $31.44 | +0.14 | +0.4% | $31.50 | $33.56 | $31.01 | 329,514 | |
| $31.30 | +0.94 | +3.1% | $30.36 | $31.57 | $29.88 | 239,518 | |
| $30.36 | -0.14 | -0.5% | $30.35 | $30.68 | $28.77 | 184,429 | |
| $30.50 | +1.70 | +5.9% | $28.91 | $31.18 | $28.91 | 369,987 | |
| $28.80 | -0.12 | -0.4% | $29.16 | $29.34 | $27.94 | 189,794 | |
| $28.92 | +1.32 | +4.8% | $27.48 | $28.92 | $26.42 | 302,649 | |
| $27.60 | +0.42 | +1.5% | $26.98 | $28.03 | $26.98 | 195,317 | |
| $27.18 | +0.78 | +3.0% | $27.14 | $27.66 | $26.01 | 270,514 | |
| $26.40 | -1.33 | -4.8% | $27.17 | $27.59 | $25.66 | 202,400 | |
| $27.73 | +2.68 | +10.7% | $25.25 | $27.83 | $24.51 | 173,100 | |
| $25.05 | -1.06 | -4.1% | $26.48 | $26.48 | $24.03 | 433,100 | |
| $26.11 | -2.74 | -9.5% | $26.51 | $28.00 | $24.63 | 426,800 | |
| $28.85 | -1.15 | -3.8% | $23.73 | $30.91 | $23.73 | 965,500 | |
| $30.00 | — | — | $28.55 | $36.49 | $22.19 | 2,284,000 |
- Ticker
- NASDAQ:LYCA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 11, 2026
Lycia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Latest news
Lycia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Nov 11, 2026
Closed $31.44 (+0.4%) on Nov 11, 2026
Lycia Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 3 in the last 12 months · 3 in all · newest Nov 11, 2026 · oldest 2026
Where Lycia Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LYCA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:LYCA | BOATS | United States | USD |
Valuation
EV/sales 237× against a median of 60.2×: the highest of 7 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.60B USD
- P/E
- Loss
- EV/sales
- 237×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- Not reported
- Operating margin
- −591.6%
- Net margin
- −540.9%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- Under 6 months of closes
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Lycia Therapeutics, Inc. · NASDAQ:LYCA | US$1.72B | US$1.60B | n/a | 237× | n/a | n/a | −540.9% | n/a | n/a |
| Vera Therapeutics, Inc. · NASDAQ:VERA | US$1.84B | US$1.53B | n/a | 149× | n/a | 5.5× | n/a | 0.2× | 1.13 |
| Hemab Therapeutics Holdings, Inc. · NASDAQ:COAG | US$1.84B | US$1.41B | n/a | n/a | n/a | 4.3× | n/a | 0.0× | 0.61 |
| Braveheart Bio, Inc. · NASDAQ:BRVE | US$1.84B | US$1.71B | n/a | n/a | n/a | 3.7× | n/a | 0.0× | n/a |
| Septerna, Inc. · NASDAQ:SEPN | US$1.84B | US$1.38B | n/a | 14.3× | n/a | 4.3× | −61.3% | 0.1× | 0.95 |
| Replimune Group, Inc. · NASDAQ:REPL | US$1.81B | US$1.60B | n/a | n/a | n/a | 8.8× | n/a | 0.5× | 0.78 |
| Neuren Pharmaceuticals Limited · ASX:NEU | US$1.76B | US$1.57B | 87.3× | 36.7× | 108× | 8.0× | 47.1% | 0.0× | n/a |
| Stoke Therapeutics, Inc. · NASDAQ:STOK | US$1.75B | US$1.43B | n/a | 50.8× | n/a | 5.0× | −862.1% | 0.0× | 0.78 |
| First Tracks Biotherapeutics, Inc. · NASDAQ:TRAX | US$1.75B | US$1.60B | n/a | n/a | n/a | 11.6× | n/a | 0.0× | 1.80 |
| Maze Therapeutics, Inc. · NASDAQ:MAZE | US$1.74B | US$1.39B | n/a | 69.6× | n/a | 4.1× | −757.4% | 0.1× | 0.66 |
| Zenas BioPharma, Inc. · NASDAQ:ZBIO | US$1.62B | US$1.26B | n/a | 114× | n/a | 7.6× | n/a | 1.1× | 1.05 |
| Median of the others | US$1.79B | US$1.48B | 87.3× | 60.2× | 108× | 5.2× | −409.3% | 0.0× | 0.87 |
Team and board
Officers
| Officer | Role |
|---|---|
| Aetna Wun Trombley | President and CEO |
| Amy Bachrodt | Chief Financial Officer |
| Winsome Chung | Senior Vice President, Finance |
| Karen Flick | General Counsel |
| Darrin Lindhout | Vice President, Head of Biologics |
| Jian Cao | Vice President, Head of CMC |
| Lynne Georgopoulos | Senior Vice President, Regulatory Affairs and Clinical Operations |
| Nadia Tchao | Vice President, Head of Early Clinical Development |
| Naomi Arana-Middendorf | Vice President, Program Management |
| Chin Lee | Chief Medical Officer |
| Sofia Touami | Chief Business Officer |
| Steve Staben | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| William J. Rieflin | Chair, Lycia Therapeutics |
| Aetna Wun Trombley | President and CEO |
| Laurent Fischer | Board Member |
Financings
| Raise | Date |
|---|---|
| Public offering of shares of common stock Closed: US$365.1M raised · US$18 a share · Jefferies +4 Dealers: Jefferies (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead), Guggenheim Securities (co-lead), LifeSci Capital | Oct 26, 2026 |
| Public offering of common stock Announced: about US$317.5M · US$18 a share · Jefferies +4 Dealers: Jefferies (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead), Guggenheim Securities (co-lead), LifeSci Capital | Oct 22, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on Oct 22, 2026.
- Price
- US$18.00 a share
- Shares offered
- 17,640,000 shares of common stock
- Offering size
- US$317.5 million
- Underwriters' option
- Up to 2,646,000 more shares
- Listing
- LYCA on the Nasdaq Global Select Market
- Underwriters
- Jefferies, TD Cowen, Evercore ISI, Guggenheim Securities, LifeSci Capital · In the order on the cover
- Shares delivered
- On or about Oct 26, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 2, 2026 |
| Filed publicly | Oct 5, 2026 |
| Amended once | Oct 20, 2026 |
| Shares registered with an exchange | Oct 20, 2026 |
| Declared effective by the SEC | Oct 22, 2026 |
| Final prospectus, with the price | Oct 23, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 23, 2026 |
| EFFECT · Notice that a registration is effective | Oct 22, 2026 |
| S-1MEF · Registration of more shares for the same offering | Oct 22, 2026 |
| CERT · Exchange's certificate of listing | Oct 22, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 20, 2026 |
| S-1/A · Registration statement, amended | Oct 20, 2026 |
| S-1 · Registration statement | Oct 5, 2026 |
| DRS/A · Draft registration statement, amended | Aug 27, 2026 |
| DRS · Draft registration statement | Jul 2, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 23, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 6.74M | 14.9M |
| Research and development | 40.5M | 41.1M |
| Selling, general and administrative | 6.11M | 6.40M |
| Operating income | -39.9M | -32.5M |
| Depreciation and amortization | 1.19M | 1.18M |
| EBITDA | -38.7M | -31.4M |
| Interest expense | 31.0K | 39.0K |
| Income before tax | -36.7M | -26.5M |
| Net income | -36.5M | -26.5M |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 19.3M | 30.6M |
| Short-term investments | 59.9M | 107.4M |
| Current assets | 80.6M | 139.8M |
| Total assets | 97.2M | 150.9M |
| Accounts payable | 996.0K | 2.27M |
| Current liabilities | 6.49M | 23.3M |
| Total liabilities | 210.6M | 228.8M |
| Shareholders' equity | -113.3M | -77.9M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -51.4M | -29.5M |
| Capital spending | -194.0K | -1.27M |
| Free cash flow | -51.6M | -30.8M |
| Cash from financing | 77.0K | 106.4M |
| Share buybacks | -3.00K | 0 |
| Change in cash | -11.3M | 17.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 26, 2026 | Insider trade | SEC |
All 40 filings
Cap table
Built by 6ix from Lycia Therapeutics, Inc.’s releases · as of Oct 26, 2026
- Common shares
- 52,094,559
- Fully diluted
- 52,094,559
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 52,094,559 | Oct 26, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 26, 2026 | 52,094,559 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Aetna Wun Trombley | President and CEO · Since at least Nov 5, 2026 |
| Amy Bachrodt | Chief Financial Officer · Since at least Nov 4, 2026 |
| Chin Lee | Chief Medical Officer · Since at least Nov 4, 2026 |
| Darrin Lindhout | Vice President, Head of Biologics · Since at least Nov 4, 2026 |
| Jian Cao | Vice President, Head of CMC · Since at least Nov 4, 2026 |
| Karen Flick | General Counsel · Since at least Nov 4, 2026 |
| Laurent Fischer | Board Member · Since at least Nov 5, 2026 |
| Lynne Georgopoulos | Senior Vice President, Regulatory Affairs and Clinical Operations · Since at least Nov 4, 2026 |
| Nadia Tchao | Vice President, Head of Early Clinical Development · Since at least Nov 4, 2026 |
| Naomi Arana-Middendorf | Vice President, Program Management · Since at least Nov 4, 2026 |
All 14 people
| Person | Seat |
|---|---|
| Sofia Touami | Chief Business Officer · Since at least Nov 4, 2026 |
| Steve Staben | Chief Scientific Officer · Since at least Nov 4, 2026 |
| William J. Rieflin | Chair, Lycia Therapeutics · Since at least Nov 5, 2026 |
| Winsome Chung | Senior Vice President, Finance · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Lycia Therapeutics, Inc.